Evidence map›Paper›PMID 42839989›Full record

ArticleFrontiers in immunology2026

Case Report: Hemophagocytic lymphohistiocytosis in an infant associated with cytomegalovirus infection and X-linked primary immunodeficiency.

Xavier García-Leon, Manuel Gómez Del Moral, Daniela Ramirez-Velasategui, Amy Mariuxi Illescas-Romero, Antonio Ramón Gómez-García, Santiago J Ballaz

Abstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xavier García-LeonDepartamento de Biología Celular e Histología, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.
Manuel Gómez Del MoralDepartamento de Biología Celular e Histología, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.
Daniela Ramirez-VelasateguiCentro de Salud Lojas-Daule, Daule, Ecuador.
Amy Mariuxi Illescas-RomeroCentro de Salud Yatubi-Bolivar, Bolivar, Ecuador.
Antonio Ramón Gómez-GarcíaEscuela de Posgrado en Salud, Universidad Espíritu Santo, Samborondón, Samborondón, Ecuador.
Santiago J BallazCentro de Investigación Biomédica (CENBIO), Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Quito, Ecuador.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory disorder often driven by primary immunodeficiencies like X-linked lymphoproliferative syndrome (XLP) in infants. Case description: We report a 2-month-old male with primary immunodeficiency who developed HLH triggered by cytomegalovirus (CMV), confirmed via bone marrow PCR and hemophagocytosis findings. Initial immunophenotyping during acute hyperinflammation showed marked secondary disruptions across lymphocyte subpopulations, including severe lymphopenia in CD4+ T cells and pre-germinal center B cells. Genetic sequencing identified a pathogenic hemizygous variant in the Conclusion: This case demonstrates an atypical XLP-2 presentation where CMV, rather than Epstein-Barr virus, triggered HLH. Following stabilization and viral clearance, the patient successfully underwent allogeneic hematopoietic stem cell transplantation (HSCT) from a matched family donor. On day +30 post-HSCT, molecular chimerism confirmed 97.87% donor engraftment. On day +39 post-HSCT, the infant is clinically stable, actively recovering at last assessment from grade II cutaneous graft-versus-host disease (GvHD) under immunosuppression, with low-level CMV viral reactivation (951 copies/mL) managed under close surveillance. At the comprehensive 9-month follow-up from initial presentation, the patient maintained overall systemic stability without evidence of disease relapse or secondary organ dysfunction, highlighting the necessity of long-term monitoring in post-transplant cGvHD management, and proving the life-saving role of early genetic diagnosis and timely HSCT.

Indexed as

Cytomegalovirus InfectionsGenetic Diseases, X-LinkedLymphohistiocytosis, HemophagocyticLymphoproliferative DisordersHematopoietic Stem Cell TransplantationHumansInfantMaleX-Linked Combined Immunodeficiency DiseasesX-Linked Inhibitor of Apoptosis ProteinXIAP protein, humanX-Linked Inhibitor of Apoptosis Proteincytomegalovirushemophagocytic lymphohistiocytosisprimary immunodeficiencyXIAP/BIRC4X-linked lymphoproliferative syndrome

Identifiers

PMID42839989
PMCPMC13638413

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.